UNSPSC 51111782: Obinutuzumab

Obinutuzumab is a humanized anti-CD20 monoclonal antibody as a cancer treatment.

UNSPSC 51111782 Obinutuzumab, a Commodity code, does not align with the recent state and local contract opportunities posted under this code. The source presents no active procurements for Obinutuzumab itself—a monoclonal antibody pharmaceutical used in oncology and hematology treatments—despite the code's assignment. Instead, the recent opportunities cluster around emergency medical services pharmaceuticals and supplies (BLS/ALS), pharmacy benefit management and dispensing services, pharmacy network qualifications, naloxone and drug deactivation systems, forensic drug reference standards, and unrelated municipal events and facility operations. None of these solicitations involve Obinutuzumab or the specialty pharmaceutical space where the code nominally sits. The mismatch suggests either miscoding by issuing bodies, a lag in taxonomic alignment with procurement intent, or a transition away from this specific therapeutic category in recent state and local purchasing activity.

The geographic spread of posted opportunities spans Florida (Collier County, Seminole County, Palm Bay, Clay County, Marion County), Wisconsin (Dane County), Oregon (Washington County), Kentucky (Owensboro), California (San Mateo County), Arizona (Tucson), Texas (West Texas Centers for Mental Health and Mental Retardation, Williamson County notice), District of Columbia, and New Mexico (Bernalillo County), but none target Obinutuzumab procurement. Representative recent solicitations under this code include Collier County's notice of intent to single source Handtevy (a mobile drug-dosage calculation application for EMS) under solicitation PUR20975, Dane County's RFP 2026RFP061PR for pharmaceutical services at Badger Prairie Health Care Center (responses due October 22, 2026), the City of Tucson Fire Department's RFP 260217 for BLS/ALS pharmaceuticals and VendNovation vending systems (proposals due June 24, 2026), and West Texas Centers' RFP RX1001 for prescription and pharmacy services across 35 service sites (proposals due August 21, 2026). The code shows minimal relevant activity for the stated commodity; vendors pursuing Obinutuzumab contracts should verify coding alignment with issuing bodies or monitor higher-tier pharmaceutical and therapeutic-product codes for accurate opportunity detection.